| Home : September 2022 : September 26, 2022 News : XNK Therapeutics to use generic name evencaleucel for lead candidate |
XNK Therapeutics to use generic name evencaleucel for lead candidate |
September 26, 2022
HUDDINGE, Sweden, Sept. 26, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International...
https://www.prnewswire.com:443/news-releases/xnk-therapeutics-to-use-generic-name-evencaleucel-for-lead-candidate-301632787.html
|
|
|
 Other Stories |
|
|
|
|
|
|
|
|
|
|
|
